A Glimmer of Hope: Eli Lilly's Bold Leap into Gene Therapy for Blinding Eye Diseases

The Unstoppable Surge: S&P 500 Earnings Power Through, Shaking Off Skepticism

The Great Economic Puzzle: Is America Really Heading for a Downturn?

The AI Infusion: How Pharma Titans Eli Lilly and Johnson & Johnson Are Teaming Up with NVIDIA to Reshape Medicine

The Looming Dawn of a New Era: How NVIDIA's Vision Is Quietly Reshaping Every Industry

A Tsunami of Pills: Eli Lilly's Grand Plan to Conquer the Weight Loss Market

Beyond the Noise: How Polen Global Growth Finds True Value in a Shifting World

A Breath of Relief: How Eli Lilly's Omvoh is Tackling Ulcerative Colitis Urgency Head-On

The Week That Was: Big Moves, Bold Bets, and Shifting Sands in the Corporate World

The Dark Side of Desire: How a UK Raid Uncovered a Multimillion-Pound Black Market in Fake Weight-Loss Drugs

A Breakthrough Moment: Unpacking Olumiant's Promise for Young Lives Touched by Alopecia

Nektar Therapeutics Stock Soars Amid Intense Takeover Speculation

The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market

Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment

A Pivotal Moment: HHS Advances Major Drug Pricing Rule for Review

Pharma's Big Win: How a Judge's Ruling Ignited Big Pharma Stocks

AbCellera Soars: A Closer Look at the Eli Lilly Partnership Fueling Stock Gains

Trump's Bold Play: Delaying Pharma Tariffs for Deeper Drug Price Deals

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition

AstraZeneca's Bold Leap: Transforming Patient Access with New Direct-to-Consumer Platform

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Eli Lilly's Groundbreaking Oral Weight-Loss Pill Set to Transform India's Obesity Battle

South Korean Pharma Giant Celltrion Seals $330M Deal for Eli Lilly's U.S. Biologics Facility

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Pfizer's Bold Leap: Eyeing Metsara in Blockbuster Acquisition Bid

Roche's Strategic Investment Ignites Excitement in the MASH Drug Development Landscape

Game Changer in Obesity Treatment: Novo Nordisk's Oral Wegovy Pill Achieves Remarkable 16.6% Weight Loss in Phase 3 Trial

FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video

Novo Nordisk Seeks Approval for Breakthrough Higher-Dose Wegovy, Promising Enhanced Weight Loss

Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope

Employers Brace for Historic Health Plan Cost Surge in 2024

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

Legal Setback: Eli Lilly's Appeal Fails, $1.8 Billion Medicaid Fraud Award Upheld

Controversial Critic Returns: Dr. Vinay Prasad Reassumes Key FDA Role

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave